Written By: Devin Golden
Vinorelbine for Mesothelioma
Vinorelbine is a chemotherapy medication for malignant mesothelioma. It’s used experimentally in clinical trials as a second- or third-line maintenance therapy or as a substitute for FDA-approved chemotherapy drugs.
Medically Reviewed By
Karen Ritter, RN BSN
Registered Nurse
Medically Reviewed By
Karen Ritter, RN BSN
Registered Nurse
JUMP TO A TOPIC
Important Facts About Vinorelbine for Mesothelioma
- Vinorelbine is not approved by the FDA for mesothelioma but is the focus of several past and present clinical studies for this cancer.
- Vinorelbine is an option as a replacement for cisplatin or pemetrexed. It’s also used on its own as an adjuvant therapy for advanced cases.
- Vinorelbine side effects include nausea, lower appetite, muscle aches and skin swelling at the infusion site.
What Is Vinorelbine?
Vinorelbine is the generic name for the brand chemotherapy drug Navelbine. It was approved in 1994 for general cancer treatment but isn’t approved yet for malignant mesothelioma.
Vinorelbine, a plant-based chemotherapy drug, is a vinca alkaloid. Its goal is to prevent cell division and replication, stifling how mesothelioma grows and spreads.
Vinorelbine interferes with cancer cells’ microtubule structures, which pull cells apart in the final stages of cell division. When these structures are blocked, the cells cannot replicate. They eventually die off before creating new cells, which is the goal of mesothelioma chemotherapy.
Vinorelbine is an option for patients enrolling in clinical trials, often after first-line chemotherapy treatment failed. Most patients either have surgery or begin with FDA-approved chemotherapy or immunotherapy before taking vinorelbine.
Vinorelbine can work in tandem with many of the other chemotherapy drugs for mesothelioma, such as:
- Cisplatin
- Pemetrexed
- Carboplatin
Survival From Vinorelbine for Mesothelioma
Vinorelbine can improve survival for patients with mesothelioma. It can extend life for late-stage patients when FDA-approved chemotherapy or immunotherapy fails. Vinorelbine can also substitute for other mesothelioma chemotherapy medications when needed.
A study in the United Kingdom tested vinorelbine on patients who had a recurrence of mesothelioma following FDA-approved systemic chemotherapy. Vinorelbine prevented cancer spread for a median of 4.2 months, which was more than one month better than people receiving just supportive care.
Vinorelbine also was successful in past studies. Doctors used the drug with cisplatin in a 2008 study. The 1-year survival rate was 61%, and the 2-year rate was 31%.
The median survival among 54 patients was 16.8 months, which outperforms cisplatin and pemetrexed by 2-4 months depending on the study. Nearly 30% of patients had some sort of response, meaning the disease either shrank or was killed completely.
Dosing of Vinorelbine
Dosing of vinorelbine varies by the study. Trials may also use a different number of cycles and doses per cycle. Vinorelbine is usually given intravenously. Some trials may test giving it via infusion.
For example, in the maintenance study comparing vinorelbine to supportive care, patients received 60 mg of vinorelbine each week (days 1, 8 and 15) during the first 21-day cycle. The dosage increased to 80 mg in the second cycle.
The study from 2008 used 25 mg doses of vinorelbine each week. The chemotherapy drug was infused over a 10-minute period.
In a phase 2 study from 2016, doctors gave patients 30 mg each week for an average of four cycles (with a high of 10 cycles). Most of the patients had an advanced case of mesothelioma (stage 3 or stage 4). Nearly 80% of patients had either stable disease or partial response to the therapy.
Vinorelbine Side Effects
Vinorelbine can cause many of the standard chemotherapy side effects, such as nausea and vomiting. Fatigue and weight loss are additional side effects to anticipate.
Others for vinorelbine include:
- Low blood counts
- Muscle weakness
- Constipation
- Diarrhea
- Burning or swelling at the site where the drug was given
How to Start Vinorelbine for Mesothelioma
If you’re interested in taking vinorelbine for mesothelioma, follow these three steps:
- Look up all the information you can about vinorelbine. Research recent survival stats, the success of past clinical trials and common side effects.
- Contact a mesothelioma patient advocate. Get in touch with these experts to make connections with the top cancer hospitals and mesothelioma doctors in the world.
- Ask an oncologist or mesothelioma specialist about vinorelbine. You may be enrolled in a clinical trial for vinorelbine, or your doctor may recommend you try the chemotherapy drug after failing other treatments.
Sources & Author
- Vinorelbine extends PFS in relapsed malignant pleural mesothelioma. Healio. Retrieved from: https://www.healio.com/news/hematology-oncology/20210607/vinorelbine-extends-pfs-in-relapsed-malignant-pleural-mesothelioma. Accessed: 06/16/2021.
- Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. U.S. National Library of Medicine. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453034/. Accessed: 05/16/19.
- Vinorelbine. Chemocare. Retrieved from: http://chemocare.com/chemotherapy/drug-info/vinorelbine.aspx. Accessed: 05/16/19.
AI Summary of Vinorelbine for Mesothelioma
Vinorelbine, known by its brand name Navelbine, is a type of chemotherapy drug that has been studied for its potential to treat malignant mesothelioma, a serious cancer often linked to asbestos exposure. Although it is not currently approved by the Food and Drug Administration (FDA) specifically for mesothelioma, vinorelbine is used in clinical trials as an option for patients when other treatments may not have been successful, or as a substitute for standard chemotherapy medications. It belongs to a class of drugs called vinca alkaloids, which work by preventing cancer cells from dividing and multiplying, thereby slowing or stopping the growth of the tumor.
Vinorelbine works by targeting the microtubule structures within cancer cells, which are essential for cell division. When these structures are blocked, the cancer cells can no longer reproduce effectively and eventually die. This mechanism can help control disease progression and, in some cases, extend survival, especially for patients with advanced mesothelioma. It is often administered through intravenous infusion, with dosage and schedule varying depending on the specific clinical trial or treatment plan. Common side effects of vinorelbine include nausea, decreased appetite, muscle aches, and swelling at the infusion site, but these can vary based on individual health conditions and treatment settings.
Research suggests that vinorelbine has the potential to improve outcomes for mesothelioma patients, especially when other treatments have failed. Studies have shown that vinorelbine can prolong periods without disease progression and may even extend overall survival in some cases. It has been used both as a standalone treatment and in combination with other chemotherapy drugs like cisplatin or pemetrexed. Patients interested in this treatment option should consult with specialized doctors and participate in clinical trials when appropriate, as ongoing research continues to explore its safety and effectiveness for mesothelioma. Understanding the potential benefits and side effects is essential for patients and their families as they navigate treatment choices for this challenging disease.